Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Perspective Therapeutics Inc (AMEX: CATX) closed at $2.81 in the last session, up 2.55% from day before closing price of $2.74. In other words, the price has increased by $2.55 from its previous closing price. On the day, 0.51 million shares were traded. CATX stock price reached its highest trading level at $2.82 during the session, while it also had its lowest trading level at $2.705.
Ratios:
We take a closer look at CATX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.66 and its Current Ratio is at 8.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On October 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $14.
On March 13, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on March 13, 2025, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 13 ’25 when Hunt Jonathan Robert bought 11,000 shares for $2.03 per share. The transaction valued at 22,295 led to the insider holds 59,800 shares of the business.
Williamson Robert F III bought 9,498 shares of CATX for $19,946 on Nov 12 ’25. The Director now owns 9,864 shares after completing the transaction at $2.10 per share. On Mar 28 ’25, another insider, Spoor Johan M., who serves as the Chief Executive Officer of the company, bought 22,026 shares for $2.24 each. As a result, the insider paid 49,384 and bolstered with 59,383 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CATX now has a Market Capitalization of 208889760 and an Enterprise Value of 38065752. For the stock, the TTM Price-to-Sale (P/S) ratio is 195.22 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 35.41 whereas that against EBITDA is -0.415.
Stock Price History:
The Beta on a monthly basis for CATX is 1.21, which has changed by -0.11912227 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, CATX has reached a high of $5.39, while it has fallen to a 52-week low of $1.60. The 50-Day Moving Average of the stock is 6.71%, while the 200-Day Moving Average is calculated to be -6.75%.
Shares Statistics:
According to the various share statistics, CATX traded on average about 1.65M shares per day over the past 3-months and 1623930 shares per day over the past 10 days. A total of 74.34M shares are outstanding, with a floating share count of 61.65M. Insiders hold about 17.07% of the company’s shares, while institutions hold 63.28% stake in the company. Shares short for CATX as of 1765756800 were 8541741 with a Short Ratio of 5.17, compared to 1763078400 on 6720024. Therefore, it implies a Short% of Shares Outstanding of 8541741 and a Short% of Float of 16.259999999999998.
Earnings Estimates
. The current rating of Perspective Therapeutics Inc (CATX) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.24 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.11 and -$1.32 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.35, with 7.0 analysts recommending between -$1.0 and -$1.98.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for CATX’s current fiscal year. The highest revenue estimate was $1.31M, while the lowest revenue estimate was $841k, resulting in an average revenue estimate of $1.07M. In the same quarter a year ago, actual revenue was $1.45M
